HengRui to the sales company "knife"! Rumors gradually hit the screen of compliance transformation of pharmaceutical companies.

Where will HengRui go when it is valued at $500 billion? Recently, E drug managerfound that Hengrui's sales company Jiangsu Xinchen Pharmaceutical Co., Ltd. is in a high-risk liquidation state, the liquidation group members are Jiangsu Hengrui Pharmaceutical Co., Ltd., Liu Chuanguang.
another sales company, Jiangsu Kexin Pharmaceutical Sales Co., Ltd., has been removed from the foreign investment by Hengrui.
Dayeye check information shows that the shareholders and the nature of Jiangsu Kexin has also changed.
Jiangsu Hengrui Pharmaceutical Co., Ltd. and Jiangsu Hengrui Pharmaceutical Group Co., Ltd. withdrew from the shareholderranks on July 13 and became Shanghai Hengrui Pharmaceutical Co., Ltd. the nature of the
enterprise is changed from a limited liability company (investment or holding by a natural person) to a limited liability company (a sole legal person who is not invested or controlled by a natural person).
industry rumors that Hengrui will clean up the two sales companies, to merge or divest them.
and Hengrui's recent multi-initiatives against the two sales companies may mean that Hengrui's cutting-edge sales reform is changing from rumor to a "real hammer".
obviously, Hengrui as a leading domestic pharmaceutical enterprises, once the opening of the sales compliance process, the industry-wide marketing methods and compliance development has a far-reaching impact on the domestic pharmaceutical enterprises sales compliance transformation will be officially opened.
the sharp sales compliance In fact, in recent times, sales compliance has once again become the industry is put in the forefront of the topic, a number of domestic and foreign companies are also caught in a series of pharmaceutical sales in the field of compliance. on July 21,
, the Ccp Hangzhou Xiaoshan Commission for Discipline Inspection/Hangzhou Xiaoshan District Supervision Commission issued a notice saying that Qian Weiwen, the former manager of Zhejiang Region of Beijing FesenYuskabi Pharmaceutical Co., Ltd., was suspected of serious violations of the law and was under investigation. On July 1,
, Shutai Shen issued a public company announcement, saying that it had received a tax processing decision, which involved nearly 80 million yuan of false VAT free text invoices, which immediately aroused industry concern and discussion.
, in addition to a number of enterprises' pharmaceutical representatives or sales staff directly in the hospital was "taken away."
Hengrui Pharmaceuticals' sales company is not very peaceful.
because employees involved in the "gold sales" case, Hengrui was also put in the forefront of public opinion, such as the end of 2019 in the Salt City Dafeng People's Hospital pharmacy director Jiang a bribery case, as well as in May this year in Zhejiang Lishui City Center Hospital, the former director of the anesthesia Lei a bribery case.
also specifically clarified this. on May 12,
, Hengrui Pharmaceuticals issued a clarification notice saying that some of the witnesses in the bribery case of doctors at a hospital in Zhejiang were employees of the company's subsidiaries.
verified that the incident was a personal act of the subsidiary employees, a serious violation of the company's management system, but also reflected the company's management loopholes.
in the future, the company will learn lessons to strengthen compliance management of its subsidiaries and prevent such incidents from happening.
and as for the two previously considered to be integrated with the two sales companies, public information shows that, as hengrui's sales company, Jiangsu Xinchen was established in 2004, specializing in Hengrui Pharmaceutical production of narcotic, pain, respiratory and liver disease in the field of drug marketing promotion.
and also established in 2004, Jiangsu Science and Technology Main Business scope for traditional Chinese medicine, chemical raw materials, chemical preparations, antibioticpreparations, biochemical drugs, biological products, psychotropic drugs (limited to category II) wholesale, sales of medical equipment.
and Heng Rui has always invested heavily in the sales company.
According to HengRui's 2019 financial results, the company's full-year sales expenses are 8.5 billion yuan, operating income is 23.3 billion yuan, sales expenses accounted for 36% of revenue.
it is worth noting that gold sales has been a long-term phenomenon in the industry.
More than 3,000 cases of commercial bribery in the pharmaceutical sector were detected from 2004 to the end of 2019, according to incomplete statistics from the China Referee Instrument Network.
compliance transformation curtain opened as a leading domestic pharmaceutical enterprises, Hengrui is clearly strengthening the control of sales channels, take Jiangsu Kexin and Xinchen two companies "knife", Hengrui's determination can be seen.
and with the strengthening of the national anti-corruption and bribery of pharmaceutical companies, the drug companies sales compliance transformation has reached the point of having to turn.
2018, the National Health and Health Commission and other nine ministries jointly issued the "2018 to correct the pharmaceutical purchase and sale of the field and medical services in the field of improper governance work points", requiring that the use of the status of pharmaceutical representatives to participate in product sales, drug authorities, commercial bribery and other acts unrelated to their work, should be included in the "black list" and reported to the relevant management departments.
April 30, 2019, shortly after The Financial Fraud case was filed, the state launched a fiscal and tax inspection of pharmaceutical companies.
May 14, 2019, the Ministry of Finance Supervision and Evaluation Bureau, in conjunction with the Fund Supervision Department of the State Medical Security Administration, in accordance with the requirements of "double random, one open" (i.e., random selection of inspection objects, random selection of law enforcement inspectors, and timely public inspection of the situation and the results of the investigation), together, a random selection of 77 pharmaceutical enterprises inspection list.
these 77 pharmaceutical enterprises involved Hengrui Pharmaceuticals, Fosun Pharma, Shanghai Pharma, Step Pharma, China Resources 39, Tianshili, Orsaikang and other 29 A-share listed companies, wholly-owned subsidiaries of listed companies, listed companies holding companies or equity companies, as well as a pharmaceutical company is a subsidiary of The Company of Hong Kong-listed companies.
according to media reports, the main content of the inspection is the cost, cost, the authenticity of income, and whether there is a private "small vault" phenomenon, whether the marketing staff's compensation payment is in compliance, whether there is a rebate phenomenon of selling rebates to medical institutions or medical personnel according to the quantity of purchased drugs, inventory management, contract signing, sales and delivery, payment and other process control is effective, whether there is a drug idling phenomenon.
subsequently, on June 4, the official website of the Ministry of Finance issued the "Ministry of Finance to carry out the 2019 inspection of the quality of accounting information in the pharmaceutical industry", and decided to organize part of the supervision authority and the local financial office (bureau) to carry out the quality inspection of accounting information in the pharmaceutical industry from June to July 2019.
closed on June 4th, Shenwan Pharmaceuticals and Bioindex fell 1.56 percent, when the biopharmaceutical industry's total market capitalisation exceeded $3.5 trillion, wiping more than 50 billion yuan off the market value of the sector in one day.
in early July, the State Administration of Taxation, Wuhan Municipal Tax Bureau inspection, has been identified as a number of pharmaceutical companies falsely issued VAT free text invoices.
other countries are strengthening the liability for commercial bribery in pharmaceutical companies.
April 24 this year, the Medical Insurance Bureau "on the establishment of drug prices and recruitment credit evaluation system guidance (draft for comments)" outflow, the pharmaceutical field commercial bribery will be blamed to pharmaceutical companies, dealers may run, but ultimately pharmaceutical companies can be used as a source, as the main body of responsibility to assume responsibility.
opinion sits that according to the nature, circumstances, timeliness, and scope of influence of pharmaceutical enterprises will be assessed as general, medium, serious, especially serious four times, serious people will lose all drugs of the network, bidding and distribution qualifications, and included in the fight against "fraud insurance" scope.
and on July 24th, the official version of the "Guidance on the Establishment of A Medical Price and Credit Evaluation System" was published on the official website of the National Health Insurance Administration.
direction has been clear, once the pharmaceutical companies suspected of commercial bribery or due to fiscal and tax problems in the East Window incident, will directly determine the survival of the enterprise.
Although the results of the fiscal and tax ations of 77 pharmaceutical companies in May 2019 have not yet been released to the public, the recent punishment judgment in the Kangmei case has been gradually implemented and can be regarded as a "bright sword" for the fiscal and taxation of pharmaceutical companies.
Kangmei Pharmaceuticals has not only been subject to the CSRC's administrative penalties, that is: the legal penalty of 600,000 yuan for Kangmei Pharmaceuticals, 21 responsible personnel were fined from 900,000 yuan to 100,000 yuan, and six main responsible persons were subject to 10 to life-long securities market ban measures.
, Kangmei Pharmaceutical Co., Ltd., the actual controller and then chairman and general manager Ma Xingtian was also suspected of illegal disclosure, non-disclosure of important information on July 10 by the public security organs to take coercive measures.
July 21, the Shanghai Stock Exchange on Ma Xingtian, Xu Dongxuan, then director, board secretary, deputy general manager Qiu Xiwei, then finance director Zhuang Yiqing, then supervisor, assistant general manager, deputy general manager Wen Shaosheng, then supervisor Ma Huanzhou, then director Ma Hanyao and a total of 21 people to publicly condemn, kangmei Pharmaceutical Co., Ltd. and related responsible persons to take disciplinary action.
proposed ma Xingtian, Xu Dongxuan, then director, board secretary, deputy general manager Qiu Xiwei life is not suitable to serve as a listed company director gao.
publicly determined that the then financial director Zhuang Yiqing, then supervisor, assistant general manager, deputy general manager Wen Shaosheng, then supervisor Ma Huanzhou 10 years is not suitable to serve as a listed company director.
and accused more than 10 people on the list of being liable for false statements in the periodic report disclosed by Theon Pharmaceuticals.
fines, prohibited from entering the market, and being subject edited by public security organs, not being able to serve as directors and supervisors of listed companies for life, and assuming legal liability... For The company's series of penalties, as well as various policy directions, is undoubtedly to alert many pharmaceutical companies determined to cure the disease early, accelerate the compliance transformation.
under the trend of tightening supervision, Hengrui has implemented comprehensive budget management, approved and strictly controlled the annual budgets of various sales branches and subsidiaries, and gradually promoted the sales transformation.
it is understood that since 2018, Hengrui Pharmaceuticals has established a product line division system, in the company level set up a cancer division, imaging division, integrated products and surgical anesthesia division, to promote the line sales reform, change the marketing model, and gradually establish a "four vertical and one horizontal" professional marketing system.
in the 2019 financial results, HengRui clearly proposed that 2020 to promote compliance transformation, vigorously grasp the transformation of sales innovation, sales cadres in the ideological and operational transformation, and vigorously enhance the ability to promote the sale of innovative drugs.
and after the latest round of compliance, where pharmaceutical companies will go, it deserves continued attention.
.